Postoperative Therapy With Infliximab Prevents Long-term Crohn's Disease Recurrence

被引:94
作者
Regueiro, Miguel [1 ,2 ]
Kip, Kevin E. [4 ]
Baidoo, Leonard [1 ,2 ]
Swoger, Jason M. [1 ,2 ]
Schraut, Wolfgang [3 ]
机构
[1] Univ Pittsburgh, Med Ctr, Ctr Inflammatory Bowel Dis, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Med Ctr, Dept Surg, Div Gastrointestinal Surg, Pittsburgh, PA 15213 USA
[4] Univ S Florida, Coll Nursing, Res Ctr, Tampa, FL USA
关键词
IBD; Anti-TNF; Clinical Trial; Tumor Necrosis Factor; Treatment; Drug; SINGLE-CENTER; POSTSURGICAL RECURRENCE; MAINTENANCE THERAPY; ADALIMUMAB; REMISSION; IMPACT; RESECTION; PLACEBO; 2-YEAR; TRIAL;
D O I
10.1016/j.cgh.2013.12.035
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: A previous randomized, placebo-controlled study showed that infliximab maintenance therapy prevented recurrence of Crohn's disease 1 year after an ileocolonic resection. We evaluated recurrence of Crohn's disease, on the basis of endoscopic examination and/or the need for additional surgical resection, beyond the first postoperative year. METHODS: In a prospective, open-label, long-term follow-up study, 24 patients previously randomly assigned to receive infliximab for 1 year after an ileocolonic resection were given the option to continue, stop, or start infliximab therapy. The primary end point was the time to recurrence of Crohn's disease, on the basis of endoscopic evidence (endoscopic recurrence), from the initial assignment to postoperative infliximab or placebo. Secondary end points were rate of endoscopic recurrence, time to reoperation, and rate of surgical recurrence in relation to the total time on infliximab. RESULTS: All patients were followed for at least 5 years after surgery. Patients assigned to the infliximab group in the first year after surgery had a longer mean time to first endoscopic recurrence (1231 +/- 747 days) than patients originally assigned to the placebo group (460 +/- 121 days, P = .003). Colonoscopies identified Crohn's disease recurrence in 22.2% of patients who received long-term infliximab and in 93.9% of those not on infliximab (P < .0001). Compared with no infliximab, the adjusted rate ratio for being in endoscopic remission while on infliximab was 13.47 (95% confidence interval, 3.52-61.53; P = .0001). Patients originally assigned to the infliximab group had a mean longer time to surgery (1798 +/- 359 days) than patients originally assigned to the placebo group (1058 +/- 529 days, P = .04). The rate of surgical recurrence (required additional surgical resection) was significantly lower among patients who received infliximab for most of the follow-up period than patients who received it for shorter periods (20.0% vs 64.3%, P = .047). CONCLUSIONS: Postoperative infliximab maintenance beyond 1 year prevents recurrence of Crohn's disease.
引用
收藏
页码:1494 / U376
页数:10
相关论文
共 28 条
[1]   Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients [J].
Aguas, Mariam ;
Bastida, Guillermo ;
Cerrillo, Elena ;
Beltran, Belen ;
Iborra, Marisa ;
Sanchez-Montes, Cristina ;
Munoz, Fernando ;
Barrio, Jesus ;
Riestra, Sabino ;
Nos, Pilar .
WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (32) :4391-4398
[2]   The impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn's disease: a single-center paired case-control study [J].
Araki, Toshimitsu ;
Uchida, Keiichi ;
Okita, Yoshiki ;
Fujikawa, Hiroyuki ;
Inoue, Mikihiro ;
Ohi, Masaki ;
Tanaka, Koji ;
Inoue, Yasuhiro ;
Mohri, Yasuhiko ;
Kusunoki, Masato .
SURGERY TODAY, 2014, 44 (02) :291-296
[3]   Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease [J].
Ardizzone, S ;
Maconi, G ;
Sampietro, GM ;
Russo, A ;
Radice, E ;
Colombo, E ;
Imbesi, V ;
Molteni, M ;
Danelli, PG ;
Taschieri, AM ;
Porro, GB .
GASTROENTEROLOGY, 2004, 127 (03) :730-740
[4]   Risk factors for surgery and postoperative recurrence in Crohn's disease [J].
Bernell, O ;
Lapidus, A ;
Hellers, G .
ANNALS OF SURGERY, 2000, 231 (01) :38-45
[5]   Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. [J].
Colombel, Jean Frederic ;
Sandborn, William J. ;
Reinisch, Walter ;
Mantzaris, Gerassimos J. ;
Kornbluth, Asher ;
Rachmilewitz, Daniel ;
Lichtiger, Simon ;
D'Haens, Geert ;
Diamond, Robert H. ;
Broussard, Delma L. ;
Tang, Kezhen L. ;
van der Woude, C. Janneke ;
Rutgeerts, Paul .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (15) :1383-1395
[6]   Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery [J].
Cosnes, J ;
Nion-Larmurier, I ;
Beaugerie, L ;
Afchain, P ;
Tiret, E ;
Gendre, JP .
GUT, 2005, 54 (02) :237-241
[7]   Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial [J].
D'Haens, Geert ;
Baert, Filip ;
van Assche, Gert ;
Caenepeel, Philip ;
Vergauwe, Philippe ;
Tuynman, Hans ;
De Vos, Martine ;
van Deventer, Sander ;
Stitt, Larry ;
Donner, Allan ;
Vermeire, Severine ;
Van De Mierop, Frank J. ;
Coche, Jean-Charles R. ;
van der Woude, Janneke ;
Ochsenkuehn, Thomas ;
van Bodegraven, Ad A. ;
van Hootegem, Philippe P. ;
Lambrecht, Guy L. ;
Mana, Fazia ;
Rutgeerts, Paul ;
Feagan, Brian G. ;
Hommes, Daniel .
LANCET, 2008, 371 (9613) :660-667
[8]  
De Cruz P, 2012, GASTROENTEROLOGY, V142, pS212
[9]   Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial [J].
Hanauer, SB ;
Korelitz, BI ;
Rutgeerts, P ;
Peppercorn, MA ;
Thisted, RA ;
Cohen, RD ;
Present, DH .
GASTROENTEROLOGY, 2004, 127 (03) :723-729
[10]   Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children [J].
Hyams, Jeffrey ;
Crandall, Wallace ;
Kugathasan, Subra ;
Griffiths, Anne ;
Olson, Allan ;
Johanns, Jewel ;
Liu, Grace ;
Travers, Suzanne ;
Heuschkel, Robert ;
Markowitz, James ;
Cohen, Stanley ;
Winter, Harland ;
Veereman-Wauters, Gigi ;
Ferry, George ;
Baldassano, Robert .
GASTROENTEROLOGY, 2007, 132 (03) :863-873